Cofactors, coreceptors, and new retroviruses. An interview with Robin A Weiss, PhD. [interview by Mark Mascolini] Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Cofactors, coreceptors, and new retroviruses. An interview with Robin A Weiss, PhD. [interview by Mark Mascolini] Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

J Int Assoc Physicians AIDS Care. 1995 Feb;1(1):6-10. Unique Identifier : AIDSLINE AIDS/95700205
Weiss RA

Abstract: Dr. Robin A. Weiss, Director of Research at the Chester Beatty Laboratories of the Institute of Cancer Research in London, England presents his thoughts on the subjects of cofactors, coreceptors, and new retroviruses in HIV infection. Dr. Weiss responds to questions in the following areas: balancing basic research and clinical trials, the importance of sheer viral load, the importance of pathogenic cofactors in HIV progression, genetic factors and susceptibility to HIV, possible reasons for long-term nonprogression, the importance of immunotherapy, the difficulty in finding a second receptor as a cofactor necessary for disease progression, and whether more human retroviruses are likely to be discovered. Among Weiss' observations are his beliefs that there should be more of a funding shift into basic research, that evidence is getting stronger for the theory that beating back the viral burden as soon as possible forestalls progression, that it appears possible that some people may have a genetic disposition against becoming HIV infected, that it is just as important to find a preinfection vaccine as it is a post-infection vaccine, and his belief that CD26 is not a coreceptor in AIDS progression.

Keywords: Disease Susceptibility/GENETICS Human HIV/ISOLATION & PURIF/*PHYSIOLOGY HIV Infections/GENETICS/PHYSIOPATHOLOGY/THERAPY Immunotherapy Receptors, Virus/*PHYSIOLOGY Survivors Viremia NEWSLETTER ARTICLE INTERVIEW
950930
M9591288

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .